ImmunoGen signs another licensing agreement with Novartis

Novartis (NVS) has signed a third agreement this year to license ImmunoGen's (IMGN) antibody-drug conjugate (ADC) technology to develop cancer therapies.

This is the fifth license that ImmunoGen has signed with a major healthcare company in 2013, with Eli Lilly and Amgen also using the tech.

The terms of the latest Novartis agreement are consistent with a license announced last month. Under a 2010 agreement, the Swiss giant pays an upfront fee to ImmunoGen for each permit, milestone payments of up to $200M, and any royalties on sales.

Surprisingly, Immunogen's shares are -4.2%. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs